Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | WNT1 | P04628 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 5/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | CPS1 | P31327 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053537 | 0.90 | DYRK1A (0.41) | GPR119DYRK1AWNT1GSK3BPIK3CA | |
| SCHEMBL16803845 | 0.89 | CPS1 (0.41) | GPR119DYRK1AWNT1GSK3BPIK3CA | |
| SCHEMBL16803836 | 0.89 | CPS1 (0.44) | GPR119PIK3CAMTORCPS1 | |
| SCHEMBL15539820 | 0.88 | MTOR (0.43) | GPR119DYRK1AWNT1PIK3CAMTOR | |
| SCHEMBL15539262 | 0.88 | MTOR (0.43) | GPR119DYRK1AWNT1PIK3CAMTOR | |
| SCHEMBL15539265 | 0.88 | MTOR (0.43) | GPR119DYRK1AWNT1PIK3CAMTOR | |
| SCHEMBL15537677 | 0.87 | PDE4B (0.42) | DYRK1AWNT1GSK3BLIPEALOX5AP | |
| SCHEMBL15539502 | 0.86 | CNR2 (0.40) | GPR119DYRK1AWNT1WDR5 | |
| SCHEMBL15539505 | 0.86 | CNR2 (0.40) | GPR119DYRK1AWNT1WDR5 | |
| SCHEMBL15537613 | 0.86 | GPR119 (0.56) | GPR119PIK3CAMTORCPS1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | claimed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | claimed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | claimed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | claimed |
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | GPR119 1/4885DYRK1A 1804/4885WNT1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.